clinical trial · NCT06643728
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company·phase2·completed·n = 252
ObesityOverweightBimagrumabTirzepatideBimagrumab PlaceboTirzepatide Placebo
brief summary
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
started
Oct 21, 2024
primary completion
Jan 16, 2026
completion
Oct 27, 2026
last updated
Nov 17, 2026
official title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol